1.60
Werewolf Therapeutics Inc Aktie (HOWL) Neueste Nachrichten
Analyzing recovery setups for Werewolf Therapeutics Inc. investorsPortfolio Growth Summary & Community Verified Trade Alerts - newser.com
Will Werewolf Therapeutics Inc. stock outperform growth indexesMarket Risk Report & Fast Gain Stock Trading Tips - newser.com
Using data tools to time your Werewolf Therapeutics Inc. exitTrade Analysis Summary & Capital Efficiency Focused Strategies - newser.com
Identifying reversal signals in Werewolf Therapeutics Inc.2025 Risk Factors & Intraday High Probability Alerts - newser.com
Werewolf Therapeutics Inc. stock trendline breakdown2025 Volatility Report & Free Expert Verified Stock Movement Alerts - newser.com
Intraday pattern recognizer results for Werewolf Therapeutics Inc.Quarterly Portfolio Review & Weekly Hot Stock Watchlists - newser.com
Predicting Werewolf Therapeutics Inc. trend using moving averagesSwing Trade & Reliable Volume Spike Alerts - newser.com
How to recover losses in Werewolf Therapeutics Inc. stockJuly 2025 Catalysts & Weekly High Momentum Picks - newser.com
Will Werewolf Therapeutics Inc. stock maintain dividend yieldQuarterly Portfolio Report & AI Enhanced Trade Execution Alerts - newser.com
Weiss Ratings Reaffirms "Sell (D-)" Rating for Werewolf Therapeutics (NASDAQ:HOWL) - MarketBeat
How high can Werewolf Therapeutics Inc. stock goEarnings Summary Report & Reliable Intraday Trade Alerts - newser.com
Werewolf Therapeutics receives FDA Fast Track for melanoma therapy By Investing.com - Investing.com Nigeria
Werewolf Therapeutics Says Investigational Melanoma Therapy WTX-124 Receives US FDA Fast Track Designation - MarketScreener
Werewolf Therapeutics receives FDA Fast Track for melanoma therapy - Investing.com
Werewolf Therapeutics receives fast track designation from the U.S. FDA for WTX-124, an investigational therapy for the treatment of cancer - MarketScreener
Werewolf Therapeutics Receives Fast Track Designation from - GlobeNewswire
Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer - Yahoo Finance
Werewolf Therapeutics Faces Nasdaq Compliance Challenge - TipRanks
Werewolf Therapeutics notifies Nasdaq of audit committee noncompliance after board member’s passing - Investing.com
Using flow based indicators on Werewolf Therapeutics Inc.Market Growth Summary & Risk Managed Trade Strategies - newser.com
Will earnings trigger a reversal in Werewolf Therapeutics Inc.2025 Institutional Moves & Long-Term Safe Investment Ideas - newser.com
Werewolf Therapeutics Inc. stock chart pattern explainedWeekly Trade Report & AI Enhanced Trade Execution Alerts - newser.com
Jefferies Initiates Werewolf Therapeutics(HOWL.US) With Buy Rating, Announces Target Price $4 - 富途牛牛
Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting - GlobeNewswire
Werewolf Therapeutics to Present Innovative Research at SITC 40th Annual Meeting - Quiver Quantitative
3 Posters: Werewolf Therapeutics to Present WTX-124, mWTX-330 Research at SITC Nov 5-9 - Stock Titan
Published on: 2025-09-30 05:19:05 - newser.com
Goldman Sachs Group Inc. Has $109,000 Stock Holdings in Werewolf Therapeutics, Inc. $HOWL - Defense World
Published on: 2025-09-30 01:50:53 - newser.com
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):